Chemoradiation provides a physiological selective pressure that increases the expansion of aberrant TP53 tumor variants in residual rectal cancerous regions

Kazuko Sakai, Shinsuke Kazama, Yuzo Nagai, Koji Murono, Toshiaki Tanaka, Soichiro Ishihara, Eiji Sunami, Shuta Tomida, Kazuto Nishio, Toshiaki Watanabe

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Neoadjuvant chemoradiotherapy has been introduced in patients with surgically resected rectal cancer and reduced the local recurrence. Heterogeneity exists in rectal cancer, and we hypothesized that there are subclones resistant to chemoradiotherapy within the cancer mass. We performed DNA-targeted sequencing of pre- and post-treatment tumor tissues obtained from 20 rectal cancer patients who received chemoradiotherapy. The variant frequency of the mutant clones was compared between pre- and post-treatment samples of nine non-responder patients. RNA-targeted sequencing of 57 genes related to sensitivity to chemotherapy and radiotherapy was performed for the paired samples. Immunohistochemical analyses of p53 expression were also performed on the paired samples from the nine non-responder patients. DNA-sequencing detected frequent mutations of suppressor genes including TP53, APC and FBXW7 in the post-treatment samples of the nine non-responders. The frequency of TP53 mutations showed significant increases after chemoradiotherapy. RNA-targeted sequencing of 29 tumor tissues demonstrated that decreased expression of three genes and increased expression of four genes were detected in the post-treatment samples. Significantly increased expression of TP53 was observed in the post-treatment samples. Immunohistochemical staining for p53 revealed that increased p53 intensity scores were observed after chemoradiotherapy. These results suggest that the tumors with TP53 mutations tend to accumulate through chemoradiotherapy.

Original languageEnglish
Pages (from-to)9641-9649
Number of pages9
JournalOncotarget
Volume5
Issue number20
Publication statusPublished - 2014
Externally publishedYes

Fingerprint

Chemoradiotherapy
Rectal Neoplasms
Neoplasms
RNA Sequence Analysis
DNA Sequence Analysis
Therapeutics
Suppressor Genes
Mutation
Mutation Rate
Genes
Radiotherapy
Clone Cells
Staining and Labeling
Gene Expression
Recurrence
Drug Therapy

Keywords

  • Chemoradiation
  • Deep sequencing
  • Rectal cancer
  • RNA sequencing
  • TP53

ASJC Scopus subject areas

  • Oncology
  • Medicine(all)

Cite this

Sakai, K., Kazama, S., Nagai, Y., Murono, K., Tanaka, T., Ishihara, S., ... Watanabe, T. (2014). Chemoradiation provides a physiological selective pressure that increases the expansion of aberrant TP53 tumor variants in residual rectal cancerous regions. Oncotarget, 5(20), 9641-9649.

Chemoradiation provides a physiological selective pressure that increases the expansion of aberrant TP53 tumor variants in residual rectal cancerous regions. / Sakai, Kazuko; Kazama, Shinsuke; Nagai, Yuzo; Murono, Koji; Tanaka, Toshiaki; Ishihara, Soichiro; Sunami, Eiji; Tomida, Shuta; Nishio, Kazuto; Watanabe, Toshiaki.

In: Oncotarget, Vol. 5, No. 20, 2014, p. 9641-9649.

Research output: Contribution to journalArticle

Sakai, K, Kazama, S, Nagai, Y, Murono, K, Tanaka, T, Ishihara, S, Sunami, E, Tomida, S, Nishio, K & Watanabe, T 2014, 'Chemoradiation provides a physiological selective pressure that increases the expansion of aberrant TP53 tumor variants in residual rectal cancerous regions', Oncotarget, vol. 5, no. 20, pp. 9641-9649.
Sakai, Kazuko ; Kazama, Shinsuke ; Nagai, Yuzo ; Murono, Koji ; Tanaka, Toshiaki ; Ishihara, Soichiro ; Sunami, Eiji ; Tomida, Shuta ; Nishio, Kazuto ; Watanabe, Toshiaki. / Chemoradiation provides a physiological selective pressure that increases the expansion of aberrant TP53 tumor variants in residual rectal cancerous regions. In: Oncotarget. 2014 ; Vol. 5, No. 20. pp. 9641-9649.
@article{7c4a91dee3e040989050ccf3ede526c9,
title = "Chemoradiation provides a physiological selective pressure that increases the expansion of aberrant TP53 tumor variants in residual rectal cancerous regions",
abstract = "Neoadjuvant chemoradiotherapy has been introduced in patients with surgically resected rectal cancer and reduced the local recurrence. Heterogeneity exists in rectal cancer, and we hypothesized that there are subclones resistant to chemoradiotherapy within the cancer mass. We performed DNA-targeted sequencing of pre- and post-treatment tumor tissues obtained from 20 rectal cancer patients who received chemoradiotherapy. The variant frequency of the mutant clones was compared between pre- and post-treatment samples of nine non-responder patients. RNA-targeted sequencing of 57 genes related to sensitivity to chemotherapy and radiotherapy was performed for the paired samples. Immunohistochemical analyses of p53 expression were also performed on the paired samples from the nine non-responder patients. DNA-sequencing detected frequent mutations of suppressor genes including TP53, APC and FBXW7 in the post-treatment samples of the nine non-responders. The frequency of TP53 mutations showed significant increases after chemoradiotherapy. RNA-targeted sequencing of 29 tumor tissues demonstrated that decreased expression of three genes and increased expression of four genes were detected in the post-treatment samples. Significantly increased expression of TP53 was observed in the post-treatment samples. Immunohistochemical staining for p53 revealed that increased p53 intensity scores were observed after chemoradiotherapy. These results suggest that the tumors with TP53 mutations tend to accumulate through chemoradiotherapy.",
keywords = "Chemoradiation, Deep sequencing, Rectal cancer, RNA sequencing, TP53",
author = "Kazuko Sakai and Shinsuke Kazama and Yuzo Nagai and Koji Murono and Toshiaki Tanaka and Soichiro Ishihara and Eiji Sunami and Shuta Tomida and Kazuto Nishio and Toshiaki Watanabe",
year = "2014",
language = "English",
volume = "5",
pages = "9641--9649",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "20",

}

TY - JOUR

T1 - Chemoradiation provides a physiological selective pressure that increases the expansion of aberrant TP53 tumor variants in residual rectal cancerous regions

AU - Sakai, Kazuko

AU - Kazama, Shinsuke

AU - Nagai, Yuzo

AU - Murono, Koji

AU - Tanaka, Toshiaki

AU - Ishihara, Soichiro

AU - Sunami, Eiji

AU - Tomida, Shuta

AU - Nishio, Kazuto

AU - Watanabe, Toshiaki

PY - 2014

Y1 - 2014

N2 - Neoadjuvant chemoradiotherapy has been introduced in patients with surgically resected rectal cancer and reduced the local recurrence. Heterogeneity exists in rectal cancer, and we hypothesized that there are subclones resistant to chemoradiotherapy within the cancer mass. We performed DNA-targeted sequencing of pre- and post-treatment tumor tissues obtained from 20 rectal cancer patients who received chemoradiotherapy. The variant frequency of the mutant clones was compared between pre- and post-treatment samples of nine non-responder patients. RNA-targeted sequencing of 57 genes related to sensitivity to chemotherapy and radiotherapy was performed for the paired samples. Immunohistochemical analyses of p53 expression were also performed on the paired samples from the nine non-responder patients. DNA-sequencing detected frequent mutations of suppressor genes including TP53, APC and FBXW7 in the post-treatment samples of the nine non-responders. The frequency of TP53 mutations showed significant increases after chemoradiotherapy. RNA-targeted sequencing of 29 tumor tissues demonstrated that decreased expression of three genes and increased expression of four genes were detected in the post-treatment samples. Significantly increased expression of TP53 was observed in the post-treatment samples. Immunohistochemical staining for p53 revealed that increased p53 intensity scores were observed after chemoradiotherapy. These results suggest that the tumors with TP53 mutations tend to accumulate through chemoradiotherapy.

AB - Neoadjuvant chemoradiotherapy has been introduced in patients with surgically resected rectal cancer and reduced the local recurrence. Heterogeneity exists in rectal cancer, and we hypothesized that there are subclones resistant to chemoradiotherapy within the cancer mass. We performed DNA-targeted sequencing of pre- and post-treatment tumor tissues obtained from 20 rectal cancer patients who received chemoradiotherapy. The variant frequency of the mutant clones was compared between pre- and post-treatment samples of nine non-responder patients. RNA-targeted sequencing of 57 genes related to sensitivity to chemotherapy and radiotherapy was performed for the paired samples. Immunohistochemical analyses of p53 expression were also performed on the paired samples from the nine non-responder patients. DNA-sequencing detected frequent mutations of suppressor genes including TP53, APC and FBXW7 in the post-treatment samples of the nine non-responders. The frequency of TP53 mutations showed significant increases after chemoradiotherapy. RNA-targeted sequencing of 29 tumor tissues demonstrated that decreased expression of three genes and increased expression of four genes were detected in the post-treatment samples. Significantly increased expression of TP53 was observed in the post-treatment samples. Immunohistochemical staining for p53 revealed that increased p53 intensity scores were observed after chemoradiotherapy. These results suggest that the tumors with TP53 mutations tend to accumulate through chemoradiotherapy.

KW - Chemoradiation

KW - Deep sequencing

KW - Rectal cancer

KW - RNA sequencing

KW - TP53

UR - http://www.scopus.com/inward/record.url?scp=84923097689&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923097689&partnerID=8YFLogxK

M3 - Article

VL - 5

SP - 9641

EP - 9649

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 20

ER -